Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

[Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer].

Küronya Z, Bíró K, Gyergyay F, Géczi L.

Orv Hetil. 2017 Jan;158(2):42-49. doi: 10.1556/650.2017.30597. Review. Hungarian.

PMID:
28088885
2.

Galeterone for the treatment of advanced prostate cancer: the evidence to date.

Bastos DA, Antonarakis ES.

Drug Des Devel Ther. 2016 Jul 15;10:2289-97. doi: 10.2147/DDDT.S93941. eCollection 2016. Review.

3.

CYP17 inhibitors in prostate cancer: latest evidence and clinical potential.

Alex AB, Pal SK, Agarwal N.

Ther Adv Med Oncol. 2016 Jul;8(4):267-75. doi: 10.1177/1758834016642370. Epub 2016 Apr 19. Review.

4.

The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.

Bird IM, Abbott DH.

J Steroid Biochem Mol Biol. 2016 Oct;163:136-46. doi: 10.1016/j.jsbmb.2016.04.021. Epub 2016 May 3. Review.

5.

Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.

Dellis A, Papatsoris AG.

Expert Opin Investig Drugs. 2016 Jun;25(6):697-707. doi: 10.1517/13543784.2016.1162784. Epub 2016 Mar 22. Review.

PMID:
26954621
6.

Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.

Crona DJ, Milowsky MI, Whang YE.

Clin Pharmacol Ther. 2015 Dec;98(6):582-9. doi: 10.1002/cpt.256. Epub 2015 Oct 1. Review.

7.

Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.

Bambury RM, Rathkopf DE.

Urol Oncol. 2016 Aug;34(8):348-55. doi: 10.1016/j.urolonc.2015.05.025. Epub 2015 Jul 7. Review.

PMID:
26162486
8.

Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations.

De Maeseneer DJ, Van Praet C, Lumen N, Rottey S.

Urol Oncol. 2015 Jul;33(7):310-21. doi: 10.1016/j.urolonc.2015.01.008. Epub 2015 Feb 21. Review.

PMID:
25708954
9.

CYP17A1 inhibitors in castration-resistant prostate cancer.

Gomez L, Kovac JR, Lamb DJ.

Steroids. 2015 Mar;95:80-7. doi: 10.1016/j.steroids.2014.12.021. Epub 2015 Jan 3. Review.

10.

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).

Gupta E, Guthrie T, Tan W.

BMC Urol. 2014 Jul 25;14:55. doi: 10.1186/1471-2490-14-55. Review.

11.

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.

Stein MN, Patel N, Bershadskiy A, Sokoloff A, Singer EA.

Asian J Androl. 2014 May-Jun;16(3):387-400. doi: 10.4103/1008-682X.129133. Review.

12.

New agents for prostate cancer.

Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J.

Ann Oncol. 2014 Sep;25(9):1700-9. doi: 10.1093/annonc/mdu038. Epub 2014 Mar 20. Review.

PMID:
24658665
13.

[Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].

Neuzillet Y, Flamand V, Lebdai S, Villers A, Lebret T.

Prog Urol. 2013 Oct;23 Suppl 1:S34-43. doi: 10.1016/S1166-7087(13)70044-7. Review. French.

PMID:
24314737
14.

CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.

Yin L, Hu Q.

Nat Rev Urol. 2014 Jan;11(1):32-42. doi: 10.1038/nrurol.2013.274. Epub 2013 Nov 26. Review.

PMID:
24276076
15.

Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.

Pinto Á.

Cancer Biol Ther. 2014 Feb;15(2):149-55. doi: 10.4161/cbt.26724. Epub 2013 Nov 1. Review.

16.

Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.

Yin L, Hu Q, Hartmann RW.

Int J Mol Sci. 2013 Jul 4;14(7):13958-78. doi: 10.3390/ijms140713958. Review.

17.

Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases.

Salvador JA, Pinto RM, Silvestre SM.

J Steroid Biochem Mol Biol. 2013 Sep;137:199-222. doi: 10.1016/j.jsbmb.2013.04.006. Epub 2013 May 18. Review.

PMID:
23688836
18.

Agents that target androgen synthesis in castration-resistant prostate cancer.

Ferraldeschi R, de Bono J.

Cancer J. 2013 Jan-Feb;19(1):34-42. doi: 10.1097/PPO.0b013e31827e0b6f. Review.

PMID:
23337755

Supplemental Content

Loading ...
Support Center